{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.\n\nDescription of Grades:\n\nGrade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death","groups":[{"id":"OG000","title":"Sorafenib + Lenalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"One participant refused further treatment prior to being assessed for adverse events.","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Number of Participants With a Grade 3 and 4 Adverse Event (Phase I)","type":"PRIMARY","unitOfMeasure":"participants"}